Fluxergy is collaborating with Mass General Brigham (MGB) to evaluate Fluxergy’s research-use-only COVID-19 molecular-testing platform. Fluxergy will work with the MGB Center for COVID Innovation, which was launched in late March. The so-called Diagnostic Accelerator is a collaboration between the Wyss Institute and Brigham and Women’s Hospital that aims to speed up the commercialization of innovative diagnostic tests.
Fluxergy’s diagnostic system comprises consumable “lab-on-chip” test cartridges called Fluxergy Cards, the Fluxergy Analyzer and FluxergyWorks software. It can provide results in under an hour, and is designed to be cost-effective and scalable, using proprietary printed circuit-board manufacturing and microfluidics technologies. See Report on Company